SELLAS Life Sciences Group, Inc.

NasdaqCM:SLS Stock Report

Market Cap: US$62.5m

SELLAS Life Sciences Group Past Earnings Performance

Past criteria checks 0/6

SELLAS Life Sciences Group's earnings have been declining at an average annual rate of -10.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 23.1% per year.

Key information

-10.5%

Earnings growth rate

58.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-23.1%
Return on equity-203.1%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

Nov 23
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jun 18
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Jul 13
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Sep 20
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

Aug 09

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Mar 08
We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Nov 23
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

Jul 19
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth

SELLAS Life Sciences updates on at-the-market offering

Jun 02

Revenue & Expenses Breakdown

How SELLAS Life Sciences Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:SLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-321220
30 Jun 240-341421
31 Mar 240-361422
31 Dec 230-371424
30 Sep 230-381425
30 Jun 230-361423
31 Mar 230-361423
31 Dec 221-411320
30 Sep 221-391218
30 Jun 221-391118
31 Mar 223-351116
31 Dec 218-211116
30 Sep 2110-181215
30 Jun 2110-151213
31 Mar 218-151112
31 Dec 202-17109
30 Sep 200-2199
30 Jun 200-2898
31 Mar 200-27107
31 Dec 190-28107
30 Sep 190-34119
30 Jun 190-32109
31 Mar 190-36129
31 Dec 180-41139
30 Sep 180-37106
30 Jun 180-32125
31 Mar 180-30116
31 Dec 170-2496
30 Sep 170-21119
30 Jun 170-231012
31 Mar 170-20612
31 Dec 160-18511

Quality Earnings: SLS is currently unprofitable.

Growing Profit Margin: SLS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SLS is unprofitable, and losses have increased over the past 5 years at a rate of 10.5% per year.

Accelerating Growth: Unable to compare SLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: SLS has a negative Return on Equity (-203.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SELLAS Life Sciences Group, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Li Wang WatsekCantor Fitzgerald & Co.
Joseph PantginisH.C. Wainwright & Co.